Answers are grounded in this paper and cite their sources.
This research reports on chitosan and polyvinylpyrrolidone nanoparticles encapsulating antimicrobials, suggesting enhanced delivery effectiveness.
Chitosan (CS) and polyvinylpyrrolidone (PVP)-based nanoparticles (NPs) are promising carriers for drug delivery due to their biocompatibility, biodegradability, and intrinsic antimicrobial properties. This study explores CS-PVP NPs for the encapsulation and controlled release of synthetic compounds (bis-THTT, JH1, JH2) and natural antimicrobials (honey and propolis). NPs were synthesized via ionic gelation, optimizing CS:PVP and CS-PVP:sodium tripolyphosphate (TPP) ratios. The optimal formulation (CS:PVP 1:0.5) produced stable, homogeneous NPs. Characterization was performed using FTIR, TGA, XRD, and AFM. Encapsulation efficiencies ranged from 44–60%. Antimicrobial activity was evaluated against Escherichia coli and Staphylococcus aureus, showing significant inhibition for JH1-, JH2-, honey-, and propolis-loaded NPs against E. coli. Cytotoxicity assays on 3T3 fibroblasts confirmed the biocompatibility of all formulations at 5 and 10 µg/mL. In vitro release studies in artificial gastric fluid (pH 1.78) demonstrated sustained drug release over 180 min. These results confirm that CS-PVP NPs can effectively encapsulate and protect both synthetic and natural bioactive compounds, enhancing their therapeutic potential. The developed nanosystems represent a versatile and safe platform for antimicrobial drug delivery and may support future applications in biomedical therapies.
No takes yet. Share an insight, caveat, or question.
Espinel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: